These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30419939)

  • 21. Should data and safety monitoring boards share confidential interim data?
    Dixon DO; Lagakos SW
    Control Clin Trials; 2000 Feb; 21(1):1-6; discussion 54-5. PubMed ID: 10659999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Data and safety monitoring board issues raised in the VA Status Epilepticus Study.
    Collins JF
    Control Clin Trials; 2003 Feb; 24(1):71-7. PubMed ID: 12559644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing training for Data Safety Monitoring Board members: A National Institute of Allergy and Infectious Diseases case study.
    Zuckerman J; van der Schalie B; Cahill K
    Clin Trials; 2015 Dec; 12(6):688-91. PubMed ID: 26152835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interim monitoring in a treatment strategy trial with a composite primary endpoint.
    Kang M; Grund B; Hunsberger S; Glidden D; Volberding P
    Contemp Clin Trials; 2019 Nov; 86():105846. PubMed ID: 31520741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.
    Bristow MR; Sharma K; Assmann SF; Linas S; Gersh BJ; Grady C; Rice MM; Singh S; Boineau R; McKinlay SM; Greenberg BH
    Eur J Heart Fail; 2017 Apr; 19(4):457-465. PubMed ID: 27873428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liability issues for data monitoring committee members.
    DeMets DL; Fleming TR; Rockhold F; Massie B; Merchant T; Meisel A; Mishkin B; Wittes J; Stump D; Califf R
    Clin Trials; 2004; 1(6):525-31. PubMed ID: 16279293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On being the statistician on a Data and Safety Monitoring Board.
    Whitehead J
    Stat Med; 1999 Dec; 18(24):3425-34. PubMed ID: 10611616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study.
    Holubkov R; Casper TC; Dean JM; Anand KJ; Zimmerman J; Meert KL; Newth CJ; Berger J; Harrison R; Willson DF; Nicholson C;
    Pediatr Crit Care Med; 2013 May; 14(4):374-83. PubMed ID: 23392377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Independent data and safety monitoring in psychiatric intervention research.
    Leon AC
    J Clin Psychiatry; 2012 Feb; 73(2):e257-63. PubMed ID: 22401486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "You have to keep your nerve on a DMC." Challenges for Data Monitoring Committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study.
    Snowdon C; Brocklehurst P; Tasker RC; Ward Platt M; Elbourne D
    PLoS One; 2018; 13(7):e0201037. PubMed ID: 30048484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A flexible futility monitoring method with time-varying conditional power boundary.
    Ying Zhang ; Clarke WR
    Clin Trials; 2010 Jun; 7(3):209-18. PubMed ID: 20423927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative Framework for Retrospective Assessment of Interim Decisions in Clinical Trials.
    Stanev R
    Med Decis Making; 2016 Nov; 36(8):999-1010. PubMed ID: 27353825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring of clinical trials and interim analyses from a drug sponsor's point of view.
    Williams GW; Davis RL; Getson AJ; Gould AL; Hwang IK; Matthews H; Shih WJ; Snapinn SM; Walton-Bowen KL
    Stat Med; 1993 Mar; 12(5-6):481-92. PubMed ID: 8493426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Data Safety Monitoring Board (DSMB).
    Welch KM
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():46-7. PubMed ID: 15512871
    [No Abstract]   [Full Text] [Related]  

  • 37. On the independence of data monitoring committee in adaptive design clinical trials.
    Chow SC; Corey R; Lin M
    J Biopharm Stat; 2012; 22(4):853-67. PubMed ID: 22651119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of futility monitoring guidelines using completed phase III oncology trials.
    Zhang Q; Freidlin B; Korn EL; Halabi S; Mandrekar S; Dignam JJ
    Clin Trials; 2017 Feb; 14(1):48-58. PubMed ID: 27590208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A joint industry-sponsored data monitoring committee model for observational, retrospective drug safety studies in the real-world setting.
    Major-Pedersen A; McCullen MK; Sabol ME; Adetunji O; Massaro J; Neugut AI; Sosa JA; Hollenberg AN
    Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):9-16. PubMed ID: 33179845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.